362
Views
3
CrossRef citations to date
0
Altmetric
Original Articles

Randomized controlled trial of individualized, low dose, fixed duration lenalidomide maintenance versus observation after frontline chemo-immunotherapy in CLL

, ORCID Icon, , , , , , , , & show all
Pages 1674-1681 | Received 03 Nov 2020, Accepted 25 Jan 2021, Published online: 21 Feb 2021
 

Abstract

Lenalidomide maintenance after frontline chemo-immunotherapy (CIT) in chronic lymphocytic leukemia (CLL) has not been standard due to the availability of novel therapies, though these remain out of reach for most in low-middle income countries. This single-center, open-label study randomized CLL patients (non-deletion 17p) after frontline therapy to lenalidomide maintenance (dose-escalated 2.5–10mg, 20/28 days per cycle for six months) or observation (2:1 allocation). Forty patients were included over 2018–2020. At a median follow-up of 22 months, median progression-free survival (PFS) with lenalidomide was not significantly different than observation (26 vs. 18 months, p = 0.4). Patients with minimal residual disease >10−2 had a trend toward better PFS with lenalidomide (19 vs. 7 months, p = 0.07). Grade 3 neutropenia was seen in 16.7% of patients on lenalidomide. Quality of life was comparable between the two arms. Low dose, fixed duration lenalidomide maintenance is not an effective strategy after frontline CIT in CLL.

Acknowledgments

The authors thank the European Hematology Association Clinical Research Training in Hematology (EHA-CRTH) team for developing the clinical trial protocol.

Support

The study drug lenalidomide was provided free of cost by Dr. Reddy's Laboratories, Hyderabad, India. However, the company was not involved in designing the study, data collection, analysis, and writing the manuscript in any form.

Author contributions

NJ, DL, and PM were involved in study conception and design. All authors contributed to patient care. Data was collected, analyzed, and draft manuscript written by NJ, DL, and PM. All authors revised the manuscript and approved the final version. DPL and NJ had full access to all the data in the study and the final responsibility to submit the paper for publication.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

Part of this work was funded by the Postgraduate Institute of Medical Education and Research intramural grant 71/2-Edu-16/190 to DL.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.